All In Biotech

Drug Trial Radar · NCT04129931

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 950 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

950

Actual

Start

Dec 19, 2019

Primary completion

Feb 19, 2025

Study completion Mar 19, 2025

Sponsor

Lead sponsor
University of North Carolina, Chapel HillAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Oct 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.

Conditions

  • Asthma

Interventions

  • MCTDrug

    Mix 2-5 packets daily into liquid or food for 16 weeks.

  • ClazakizumabDrug

    12.5 mg subcutaneous injection given once every 4 weeks for 16 weeks. Lab driven dose reductions will be made based on safety lab data. If criteria are met for dose reduction, the participant will be reduced to a 6.25 mg dose.

  • Broncho-VaxomDrug

    7 mg taken orally once a day, on an empty stomach, for 16 weeks

  • Imatinib MesylateDrug

    Two 100 mg tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. If the drug is well tolerated, participants will titrate up to four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Safety labs will be collected at each study visit to monitor the tolerability of each participant.

  • CavosonstatDrug

    50 mg capsule orally twice a day for 16 weeks.

  • PlaceboOther

    MCT Matching Placebo: MCT matching placebo packets. Mix 2-5 packets daily into liquid or food for 16 weeks. Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks. Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Forced Expiratory Volume in One Second (FEV1) Percent PredictedTime frame: Measured at 16 weeks after the start of treatment.
  2. The Juniper Asthma Control Questionnaire (ACQ-6)Time frame: Measured at 16 weeks after the start of treatment.

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • University of Arizona Tucson

    Tucson, Arizona

  • University of California Davis

    Sacramento, California

  • University of California San Diego: Airway Research & Clinical Trials Center

    San Diego, California

  • University of California San Diego: La Jolla Altman Clinical Translation Research Institute

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • University of Colorado Denver

    Aurora, Colorado

  • National Jewish Health

    Denver, Colorado

  • Yale University

    New Haven, Connecticut

  • University of South Florida

    Tampa, Florida

  • University of Illinois at Chicago

    Chicago, Illinois

  • Ann & Robert H. Lurie Children's Hospital

    Chicago, Illinois

  • Northwestern Universtiy

    Chicago, Illinois

  • Rush University

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Riley Hospital for Children

    Indianapolis, Indiana

  • University of Kansas

    Kansas City, Kansas

  • Boston Children's Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Washington University

    St Louis, Missouri

  • Mount Sinai

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Wake Forest University

    Winston-Salem, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • University Hospitals Rainbow Babies & Children's Hospital

    Cleveland, Ohio

  • Vanderbilt University

    Nashville, Tennessee

  • University of Wisconsin-Madison

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.